GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of … – StreetInsider.com

GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of
StreetInsider.com
GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 …
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
FDA approves Glaxo's inhaler drug Breo Ellipta for new use in treating adults Minneapolis Star Tribune

all 2 news articles »

View full post on asthma – Google News